…… 在过去的几天里，我们已见证了《全球医疗大挑战》项目的几个真正有希望的例子。

　　我请你们特别注意其中的一个，因为这一个就在中国。

　　正如你们许多人所知道的，肺结核是最致命的疾病之一：全球每年有900万新发病例，其中的三分之一没有得到诊断。

　　全球控制结核的努力，因为缺乏快速、准确、并且低价的诊断工具而进展缓慢，特别是在非洲的撒哈拉地区。

　　杭州优思达生物技术有限公司是一家民营的中国诊断公司。该公司的科学家们在2011年7月赢得了加拿大《大挑战》项目的资助，用于开发快速肺结核诊断技术。最初的资助为240万加元。

　　此后比尔和美琳达. 盖茨基金会又向优思达投资了1130万美元，用于开发、生产和销售新的诊断系统。

　　除了财务支持，我们基金会还向优思达提供了技术支持，使其能够为发展中国家生产诊断产品……

　　Sue Desmond-Hellmann, CEO, Bill & Melinda Gates Foundation

　　Grand Challenges Closing Plenary Keynote

　　Event Date: October 21, 2015

　　“… Over the last few days, we’ve seen several examples of Grand Challenges projects that are showing genuine promise.

　　I’ll call attention to just one of them, and it’s from right here in China.

　　As many of you are quite aware, tuberculosis is one of the leading causes of death worldwide, with an estimated 9 million new cases each year—one-third of them undiagnosed.

　　TB-control efforts worldwide—particularly in Sub-Saharan Africa—suffer from a lack of low-cost diagnostic tests that are fast and accurate.

　　Scientists at Ustar Biotechnologies, a privately-held Chinese diagnostics company, won the Grand Challenges Canada award in July 2011 for its focus on developing rapid TB-diagnostic technologies. The initial grant was worth a total of 2.4 million Canadian dollars.

　　The Bill & Melinda Gates Foundation then invested another 11.3 million U.S. dollars in Ustar for the development, manufacture, and delivery of a new low-cost diagnostic kit.

　　In addition to this financial backing, our foundation also provides Ustar with technical support to generate products for the developing world ...”